Diagnosis

There is no perfect test for SIBO. Diagnosis usually combines symptoms, risk factors, exclusion of alternative conditions, and testing when appropriate.

Breath Testing

Hydrogen and methane breath tests are commonly used. The patient drinks a sugar substrate, commonly glucose or lactulose. Breath samples are collected over time to measure gases produced by intestinal microbes.

Commonly measured gases include:

hydrogen
methane
sometimes hydrogen sulfide, depending on test availability

Glucose vs Lactulose

Glucose and lactulose breath tests behave differently.

Glucose is absorbed in the proximal small intestine, which may make it less likely to detect distal overgrowth. Lactulose is not absorbed and travels through the intestine, but results may be affected by intestinal transit time.

Neither test is perfect.

Methane and Constipation

Methane positivity is often discussed in patients with constipation-predominant symptoms. Some clinicians use the term intestinal methanogen overgrowth because methane is produced by archaea rather than bacteria.

Test Preparation

Preparation instructions vary by laboratory. Patients are commonly asked to follow specific diet restrictions before the test and to avoid selected medications, laxatives, probiotics, or antibiotics for defined periods.

Follow the instructions from the ordering clinician or laboratory. Incorrect preparation can make results harder to interpret.

Limitations

Breath test results can be affected by:

rapid transit
slow transit
recent antibiotics
laxatives
colonoscopy preparation
diet before the test
smoking or exercise during the test
substrate selection
interpretation criteria

Practical interpretation

A positive test can support SIBO when the clinical picture fits. A negative test does not always exclude it. Results should be interpreted by a clinician familiar with the patient's symptoms and risk factors.

Alternative Testing

Small bowel aspirate culture can be obtained during endoscopy in selected cases. It is invasive, less commonly used, and has technical limitations.

Broader Evaluation

Depending on the presentation, clinicians may also consider evaluation for:

celiac disease
inflammatory bowel disease
anemia
thyroid disease
pancreatic insufficiency
bile acid diarrhea
infection
medication effects
nutritional deficiencies

SIBO, IBS, and Visceral Hypersensitivity

SIBO, irritable bowel syndrome (IBS), and visceral hypersensitivity are often discussed as if they are separate diagnoses. In practice, they often overlap. A single person can meet symptom criteria for IBS, have a positive SIBO breath test, and also have a sensitized gut nervous system that amplifies pain, bloating, or meal-related symptoms.^[1]^[2]^[3]

The practical diagnostic question is not always “which one is it?” A better question is: how much is each mechanism contributing to this patient’s symptoms?

Three layers of the same symptom pattern

These conditions can produce similar symptoms, including bloating, abdominal pain, gas, diarrhea, constipation, and meal-related discomfort. They describe different layers of the problem:

SIBO is a microbiologic problem: excessive or abnormal microbes in the small intestine can ferment carbohydrates, produce gas, injure the mucosa in severe cases, and contribute to diarrhea or malabsorption.^[1]^[4]
IBS is a clinical syndrome: Rome IV criteria define IBS by recurrent abdominal pain related to defecation and/or a change in stool frequency or form, after appropriate evaluation for alarm features or other diseases.^[2]^[5]
Visceral hypersensitivity is a neurophysiologic mechanism: the gut becomes more sensitive to normal stretching, gas, meals, or intestinal movement. It is common in IBS and is usually studied with specialized research tests rather than routine clinical testing.^[2]^[6]

Key idea

IBS is the symptom pattern. SIBO and visceral hypersensitivity are two possible mechanisms that can sit underneath that pattern. They can coexist.

How they interact

SIBO and IBS have a complicated relationship. Some patients with IBS-like symptoms have evidence of bacterial overgrowth, but breath testing is imperfect and not every positive test proves that SIBO is the main driver of symptoms.^[1]^[7]^[8]

Meta-analyses show that positive SIBO testing is more common in IBS than in controls, especially in studies using breath testing. One 2020 case-control meta-analysis found SIBO was more common in IBS, with an odds ratio of 3.7 overall and 4.9 in studies using healthy controls; breath-test-positive SIBO was present in 35.5% of IBS patients vs 29.7% of controls.^[8] A newer 2026 meta-analysis also supports an association between IBS and SIBO and suggests rifaximin can help some patients with IBS and concomitant SIBO, though test methods and populations remain heterogeneous.^[9]

SIBO may contribute to hypersensitivity through immune activation, altered permeability, bacterial products, and low-grade inflammation. This is biologically plausible and supported by mechanistic and animal-model data, but it does not mean every patient with visceral hypersensitivity has active SIBO.^[3]^[10]

Visceral hypersensitivity is one of the major mechanisms within IBS. In five cohorts totaling 1,144 patients with functional GI disorders, visceral hypersensitivity correlated with GI symptom severity independent of anxiety, depression, and somatization.^[6]

Clinical comparison

Feature	SIBO	IBS without clear SIBO	Visceral hypersensitivity
What it describes	Microbial overgrowth or dysbiosis in the small intestine	Symptom-based disorder of gut-brain interaction	Lower pain or discomfort threshold to gut distension
Typical diagnostic approach	Glucose or lactulose breath test; small bowel aspirate in selected cases	Rome IV criteria plus evaluation for alarm features and mimics	Mostly research testing, such as rectal barostat; not routine clinical care
Symptoms that raise suspicion	Diarrhea, bloating, gas, sometimes steatorrhea or deficiencies in severe disease	Recurrent abdominal pain linked to stool change or defecation	Pain or bloating out of proportion to objective findings; meal-related symptom amplification
Risk clues	Prior intestinal surgery, blind loop, strictures, scleroderma, diabetes with dysmotility, opioids, motility disorders	Post-infectious onset, food triggers, stress-related flares, female sex, overlapping gut-brain symptoms	Post-infectious symptoms, central sensitization, mast cell or immune activation, psychological stress amplifying symptoms
Malabsorption signs	Possible in severe or structural cases	Absent	Absent
Treatment implication	Antibiotics and correction of underlying risk factors may help selected patients	IBS-directed diet, bowel-pattern treatment, gut-brain therapies, neuromodulators when appropriate	Neuromodulators, gut-directed behavioral therapy, and treating the trigger if one is found

When to suspect SIBO

Testing for SIBO is most useful when the clinical story makes bacterial overgrowth plausible, not simply because bloating is present. Consider discussing testing with a clinician when there are:

clear risk factors, such as prior gastric or intestinal surgery, blind loop anatomy, strictures, scleroderma, chronic opioid use, or diabetes with autonomic neuropathy^[1]^[7]
diarrhea-predominant symptoms, especially when diarrhea is more prominent than pain^[7]^[11]
signs of malabsorption, such as unexplained weight loss, steatorrhea, vitamin B12 deficiency, iron deficiency, or fat-soluble vitamin deficiency^[1]^[7]
recurrent symptoms after an initial SIBO response, especially if the underlying motility or structural risk factor remains

The ACG guideline supports breath testing in selected symptomatic patients, but the AGA urges caution because SIBO definitions and breath test interpretation remain imperfect.^[1]^[7] The AGA bloating update specifically advises against routine SIBO testing for bloating and distention unless clear risk factors or severe symptoms justify a test-and-treat approach.^[11]

When IBS or hypersensitivity may be dominant

SIBO may be less likely to be the only driver when symptoms are pain-predominant, strongly stress-responsive, or persist despite adequate treatment and reassessment. Residual symptoms after SIBO treatment can reflect ongoing constipation, dietary triggers, pelvic floor dysfunction, bile acid diarrhea, inflammatory disease, medication effects, or a sensitized gut nervous system.

Visceral hypersensitivity is more likely to be important when:

pain or bloating feels disproportionate to objective findings
symptoms flare after meals even without clear malabsorption
symptoms persist after SIBO eradication or after repeated antibiotics
there are overlapping disorders of gut-brain interaction
anxiety, depression, hypervigilance, or prior infection amplifies symptom burden, even if these are not the original cause

Rectal barostat testing is the best-validated research method for measuring visceral sensitivity, but it is not a routine clinical test.^[12] The lactulose nutrient challenge test is an emerging noninvasive research tool for meal-related symptoms in IBS, but it is not yet a standard diagnostic test.^[13]

Avoid the antibiotic loop

Repeated bloating or pain does not automatically mean recurrent SIBO. Repeating antibiotics without reassessing the diagnosis can miss other causes and may add side effects or microbiome disruption.

References

ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. Pimentel M, Saad RJ, Long MD, Rao SSC. The American Journal of Gastroenterology. 2020;115(2):165-178. <doi:10.14309/ajg.0000000000000501>
Irritable Bowel Syndrome. Ford AC, Sperber AD, Corsetti M, Camilleri M. Lancet (London, England). 2020;396(10263):1675-1688. <doi:10.1016/S0140-6736(20)31548-8>
Small Intestinal Bacterial Overgrowth: A Framework for Understanding Irritable Bowel Syndrome. Lin HC. JAMA. 2004;292(7):852-858. <doi:10.1001/jama.292.7.852>
Chronic, Noninfectious Diarrhea: A Review. Singh P, Lee A, Sheth NM, Chey WD. JAMA. 2026;335(14):1250-1262. <doi:10.1001/jama.2026.0872>
Review Article: Diagnosis and Investigation of Irritable Bowel Syndrome. Black CJ. Alimentary Pharmacology & Therapeutics. 2021;54 Suppl 1:S33-S43. <doi:10.1111/apt.16597>
Visceral Hypersensitivity Is Associated With GI Symptom Severity in Functional GI Disorders: Consistent Findings From Five Different Patient Cohorts. Simren M, Tornblom H, Palsson OS, et al. Gut. 2018;67(2):255-262. <doi:10.1136/gutjnl-2016-312361>
AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review. Quigley EMM, Murray JA, Pimentel M. Gastroenterology. 2020;159(4):1526-1532. <doi:10.1053/j.gastro.2020.06.090>
Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control Studies. Shah A, Talley NJ, Jones M, et al. The American Journal of Gastroenterology. 2020;115(2):190-201. <doi:10.14309/ajg.0000000000000504>
Relationship Between Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome and the Efficacy of Rifaximin Intervention: A Systematic Review and Meta-Analysis. Lu H. Frontiers in Microbiology. 2026;17:1780567. <doi:10.3389/fmicb.2026.1780567>
Functional Gastrointestinal Disorders: Advances in Understanding and Management. Black CJ, Drossman DA, Talley NJ, Ruddy J, Ford AC. Lancet (London, England). 2020;396(10263):1664-1674. <doi:10.1016/S0140-6736(20)32115-2>
AGA Clinical Practice Update on Evaluation and Management of Belching, Abdominal Bloating, and Distention: Expert Review. Moshiree B, Drossman D, Shaukat A. Gastroenterology. 2023;165(3):791-800.e3. <doi:10.1053/j.gastro.2023.04.039>
Irritable Bowel Syndrome: Methods, Mechanisms, and Pathophysiology. Methods to Assess Visceral Hypersensitivity in Irritable Bowel Syndrome. Keszthelyi D, Troost FJ, Masclee AA. American Journal of Physiology. Gastrointestinal and Liver Physiology. 2012;303(2):G141-G154. <doi:10.1152/ajpgi.00060.2012>
Hypersensitivity to the Lactulose Nutrient Challenge Test in Irritable Bowel Syndrome: A Noninvasive Test of Meal-Related Symptoms. Algera JP, Melchior C, Colomier E, Tornblom H, Simren M. The American Journal of Gastroenterology. 2025. <doi:10.14309/ajg.0000000000003843>

Updated 3 Jun 2026